Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis

Pediatric Pulmonology

Volumn 47, Issue 2, 2012, Pages 125-134

  Mayer Hamblett, Nicole ^a,b   Kronmal, Richard A ^c   Gibson, Ronald L ^a,b   Rosenfeld, Margaret ^a,b   Retsch Bogart, George ^d   Treggiari, Miriam M ^c   Burns, Jane L ^a,b   Khan, Umer ^b   Ramsey, Bonnie W ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

clinical outcome; early intervention; eradication; new acquisition

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; PLACEBO; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECURRENCE; RISK; TOBRAMYCIN; TREATMENT FAILURE;

EID: 84855892151     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21525     Document Type: Article

References (25)

1. Ratjen F, Döring G,. Cystic fibrosis. Lancet 2003; 361: 681-689. (Pubitemid 36246556)
2. Gibson RL, Burns JL, Ramsey BW,. State of the art: pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-951. (Pubitemid 37267172)
3. Henry RL, Mellis CM, Petrovic L,. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12: 158-161.
4. Courtney JM, Bradley J, Mccaughan J, O'Connor TM, Shortt C, Bredin CP, Bradbury I, Elborn JS,. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007; 42: 525-532. (Pubitemid 46870384)
5. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K,. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138: 699-704. (Pubitemid 32417671)
6. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL,. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100. (Pubitemid 34809519)
7. Pamukcu A, Bush A, Buchdahl R,. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995; 19: 10-15.
8. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE,. Epidemiologic study of cystic fibrosis. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004; 37: 400-406. (Pubitemid 38620061)
9. Kerem E, Corey M, Gold R, Levison H,. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990; 116: 714-719. (Pubitemid 20162819)
10. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151: 134-139
11. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, Green CG, Collins J, Farrell PM,. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32: 277-287. (Pubitemid 32938876)
12. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW,. EPIC Study Group. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the epic clinical trial and observational study. Contemp Clin Trials 2009; 30: 256-268.
13. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Ramsey BW, for the EPIC Investigators. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011.
14. Mayer-Hamblett N, Burns JL, Khan U, Retsch-Bogart G, Treggiari M, Ramsey BW,. Predictors of Pseudomonas aeruginosa recurrence in cystic fibrosis: results from the EPIC trial. Pediatr Pulmonol 2010; Supplement 23: 326.
15. Therneau TM, Grambsch PM,. Modeling survival data: Extending the Cox model (Statistics for biology and health). Rochester, MN: Mayo Foundation; 2000.
16. McKone EF, Emerson SS, Edwards KL, Aitken ML,. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361: 1671-1676. (Pubitemid 36577438)
17. McKone EF, Goss CH, Aitken ML,. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006; 130: 1441-1447. (Pubitemid 44786738)
18. Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL, EPIC Study Group Participating Clinical Sites. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol 2010; 45: 934-944.
19. Valerius NH, Koch C, Høiby N,. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338: 725-726.
20. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, von der Hardt H,. Placebo-controlled, double-blind, randomised study of aerosolised tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25: 88-92. (Pubitemid 28110583)
21. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841-849. (Pubitemid 36801771)
22. Proesmans M, Boulanger L, Vermeulen F, De Boeck K,. Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin/ciprofloxacin [abstract]. J Cyst Fibros 2008; 7: S64.
23. Langton Hewer SC, Smyth AR,. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009; CD004197. Review.
24. Ratjen F, Munck A, Kho P, Angyalosi G, ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65: 286-291 (Epub Dec 8, 2009).
25. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM,. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2: 29-34. (Pubitemid 36857407)